← Leaderboards
Daniel G. Stover
Broad Institute, Inc.
$777,584
Attributed
$1,915,935
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $711.8K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,915,935 · 4
By mechanism
UH3$761,769 · 1
R01$437,753 · 1
R21$395,878 · 1
UH2$320,535 · 1
Top collaborators
- Viktor Adalsteinsson5 shared
- Niall John Lennon5 shared
- Ramesh K Ganju1 shared
- Leigha Senter-Jamieson1 shared
Others in their field
Other Emerging Leaders on “Innovation”
- Klaus Romero · Critical Path Institute$86,053,372
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$69,953,681
- Tony Moody · Duke University$65,625,959
- Matthew Johnson · Duke University$60,590,296
Research focus
InnovationTumorMalignant Breast NeoplasmSamplingTissue BanksMetastatic Breast CancerMutateMalignant NeoplasmsBreastTriple-Negative Invasive Breast CarcinomaProspectiveQuality Of LifeGenesCancer TypeCollaborationsBloodDetectionBiopsyCost EffectiveGenomic BiomarkerIneffective TherapiesAssay DevelopmentAndrogen ReceptorComputational Pipelines
Grant awards (7)
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$193,674
UH3 · FY2024 · CA
Addressing cancer disparity through defining the molecular link between breast feeding and triple negative breast cancer$437,753
R01 · FY2023 · CA · contact PI
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$274,067
UH3 · FY2023 · CA
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$294,028
UH3 · FY2022 · CA
Video Intervention to Address Pre-Test Patient Education for Tumor Genomic Testing$395,878
R21 · FY2021 · CA · contact PI
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$105,636
UH2 · FY2021 · CA
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$214,899
UH2 · FY2020 · CA